September 18 Biotech Update

Not much happening in the sector or markets outside of the ongoing issues in the Middle East. We will likely get a press conference today that blames Iran for the.

September 17 Biotech Update

So I was thinking that any response to the attacks on Saudi Arabia would happen sooner rather than later but I am no longer convinced that remains the case.  Clearly.

September 16 Biotech Update

It is looking like a macro week, although this could resolve itself fairly quickly.  The attacks on the ARAMCO production facility is likely to have long term effects on oil.

Initiating: Turning Point Therapeutics

San Diego based Turning Point Therapeutics is an oncology focused biotech that completed a successful IPO in April this year, raising about $190M with pricing at $18/sh. As the stock.

September 11th Biotech Update

(Sorry for the delay.  The site worked but we had an issue with posting new articles.  It is now fixed) The resilience of the sector is a little surprising and.

September 10 Biotech Update

Surprise.  The sector is weak.  I am a little surprised that we are not see a faster sell off as clearly there is no momentum and we have broken support. .

September 9th Biotech Update

We have some interesting news to start the week and of course it leads to a flat sector with the broader market green.  It seems like the sector is underperforming.

September 5th Biotech Update

I have class about to begin but I want to put out a quick note on the news. GBT announced that the FDA has accepted the NDA for voxelotor with.

ARQL- Quick Take

I have been following Arqule off and on for quite some time. The company has been reborn after so many lost years pursuing its failed MET inhibitor ARQ 197. Hopes.

September 4th Biotech Update

The sector is in an odd spot.  It seems to be right under a major support but has not quite broken down.  I suspect we cannot remain at these levels.

September 3 Biotech Update

We remain in the summer doldrums but more than that we are stuck in the macro issues. Between a potential recession to the China trade war, it is virtually impossible.

August 29th Biotech Update

I will keep this short and sweet as there is little news to talk about. On the positive side, the sector seems to be doing better and while I would.

August 28 Biotech Update

I think today is the day. The sector is at a very precarious positon. It has dropped below what was support but I still think it has a chance to.

Zogenix Acquires Modis Therapeutics

Aug 27, 2019 by Jason Chew Zogenix announced yesterday that it is acquiring privately held Modis Therapeutics. It gains access to the late stage substrate enhancement therapy, MT1621, for the.

August 26 Biotech Update

Market starts the week higher but I do not trust it as there is the old saying that markets never bottom on Fridays. To be fair futures were down a.

Coverage Continuation- ARVN

Aug 23, by Jason Chew Arvinas is one of the newer names I’ve been covering. The company is developing a new class of drugs with a new modality known as.

August 23 Biotech Update

So the sector feels a lot worse than the chart indicates. We are right around support at $80 and that seems to have been holding. We are approaching, however, a.

August 21 Biotech Update

Broadly speaking the sector and market are doing well. Sentiment has been pretty negative and there were some macro concerns. This seems to be easing a bit, so a rally.

August 20th Biotech Update

So I do not want to spend a lot of time on macro or the sector as it is the same but we do have some really important news to.

Coverage Continuation- ZGNX

Aug 19, 2019 by Jason Chew Zogenix ran into some unwelcome surprise this April when FDA kicked back its ZX008 (Fintepla) NDA with a Refuse to File letter. The two deficiencies cited.

Browsing 20 / 4 articles